.png/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:806,h:676)
Together we can bring hope for sight & sound
About Us
Meet Our Team
Meet Our Team
We are an organisation that aims to increase awareness and understanding of Usher syndrome, be a trusted source of information, along with raising funds for scientific research to find a cure or treatment for Usher syndrome. You can learn more about us and read our mission statement here.
Meet Our Team
Meet Our Team
Meet Our Team
Our organisation is run entirely by passionate volunteers meaning there's no paid staff and no team member is paid for their time or work. Therefore, we truly appreciate the dedication each one gives to help further the cause of Usher Syndrome Ireland. Read more about each of our amazing team members and why they became involved.
Latest News:
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Recently, Usher Syndrome Ireland successfully hosted its first-ever event, Connecting the Community, bringing together for the very first time in Ireland the Usher syndrome community.
Usher Syndrome Ireland on Ireland AM
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Our board member Deirdre, and Prof Keegan, recently appeared on national TV on Ireland:AM, to raise awareness of Usher syndrome and Usher Syndrome Ireland. You can watch back by searching episode number:128 on Virgin Media Player.
Nacuity SLO-RP Study
Usher Syndrome Ireland Hosts its First-Ever Event - Connecting the Community
Nacuity SLO-RP Study
Nacuity has begun its Phase 1/2 clinical trial of Nacuity’s proprietary NPI-001 tablets, the SLO-RP Study, and are now enrolling patients with RP associated with Usher syndrome. This therapy focuses on the treatment of ocular oxidative stress in the retina which they believe may potentially slow down the degeneration of the photoreceptors cells as experienced by patients with RP associated with Usher syndrome. Nacuity expects to report interim safety results from this study during the third quarter of 2022 and first efficacy results second quarter 2023. More information can be found here.
PROUD MEMBERS AND PARTNERS OF:
Kindly supported by:
